Third-Generation Cephalosporin — Pseudomonas / Gram-Negative Infections
Pregnancy: Safe — cephalosporins considered safe in pregnancy
Ceftazidime
Brand names: Fortum, Kefadim
Adult dose
Dose: 1–2 g IV every 8 hours; Pseudomonal infections: 2 g IV every 8 hours; Cystic fibrosis exacerbation: 2 g every 8 hours
Route: Intravenous (or IM for mild infections)
Frequency: Every 8 hours
Max: 9 g/day
One of few beta-lactams with reliable Pseudomonas aeruginosa activity. Used in febrile neutropenia, Pseudomonal pneumonia, cystic fibrosis, meningitis (gram-negative), complicated UTI. No MRSA activity. Extended infusion (4-hour) may improve PK/PD target attainment against resistant organisms.
Paediatric dose
Dose: 25–50 mg/kg mg/kg
Route: IV
Frequency: Every 8 hours
Max: 6 g/day
BNFc: neonates — 25 mg/kg every 12–24 hours (age-dependent); widely used in paediatric febrile neutropenia
Dose adjustments
Renal
CrCl 31–50: 1 g every 12 hours; CrCl 16–30: 1 g every 24 hours; CrCl 6–15: 500 mg every 24 hours; CrCl <5: 500 mg every 48 hours
Hepatic
No dose adjustment required
Paediatric weight-based calculator
BNFc: neonates — 25 mg/kg every 12–24 hours (age-dependent); widely used in paediatric febrile neutropenia
Clinical pearls
- Ceftazidime-avibactam (Zavicefta) is a new combination agent for carbapenem-resistant gram-negatives (KPC, OXA-48, ESBL) — becoming critically important for MDR organisms
- Pseudomonal empiric coverage in febrile neutropenia — ceftazidime or piperacillin-tazobactam are standard first-line options per ECIL guidelines
- Neurotoxicity risk in renal failure: dose reduction essential — encephalopathy, myoclonus, seizures from beta-lactam accumulation in CNS
- Extended infusion (4 hours) optimises time above MIC for intermediate-resistant organisms — used in specialist centres for difficult-to-treat infections
Contraindications
- Cephalosporin hypersensitivity
- Penicillin anaphylaxis (cross-reactivity)
Side effects
- GI disturbance
- Eosinophilia
- Elevated LFTs
- Phlebitis (IV)
- Neurotoxicity (seizures — especially in renal failure)
- C. difficile
- Rash
Interactions
- Warfarin — enhanced effect
- Aminoglycosides — synergistic for Pseudomonas (often combined)
- Probenecid — increases levels
- Nephrotoxic drugs — additive if combined with aminoglycosides
Monitoring
- Renal function (dose adjustment)
- Neurotoxicity (confusion, myoclonus) — especially in renal failure
- LFTs
- FBC (eosinophilia)
- C. difficile if diarrhoea
Reference: BNFc; BNF 90; ECIL Guidelines Febrile Neutropenia; IDSA Guidelines Pseudomonas; PHE Antibiotic Guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- Dengue Severity Classification (WHO 2009) · Tropical Infections
- Malaria Severity Assessment (WHO Criteria) · Tropical Infections
- Toxoplasmosis Risk Assessment (Congenital and Immunocompromised) · Parasitic Infections
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
Pathways